Doug Marchion
Doug Marchion
Research Scientist, Moffitt Cancer Center
Dirección de correo verificada de
Citado por
Citado por
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
P Münster, D Marchion, E Bicaku, M Schmitt, JH Lee, R DeConti, ...
Journal of Clinical Oncology 25 (15), 1979-1985, 2007
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster
Cancer research 65 (9), 3815-3822, 2005
ABCG2 expression, function, and promoter methylation in human multiple myeloma
JG Turner, JL Gump, C Zhang, JM Cook, D Marchion, L Hazlehurst, ...
Blood 108 (12), 3881-3889, 2006
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway
PN Münster, DC Marchion, AD Basso, N Rosen
Cancer research 62 (11), 3132-3137, 2002
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
DC Marchion, E Bicaku, AI Daud, V Richon, DM Sullivan, PN Munster
Journal of cellular biochemistry 92 (2), 223-237, 2004
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
PN Munster, D Marchion, S Thomas, M Egorin, S Minton, G Springett, ...
British journal of cancer 101 (7), 1044-1050, 2009
Development of histone deacetylase inhibitors for cancer treatment
D Marchion, P Münster
Expert review of anticancer therapy 7 (4), 583-598, 2007
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC
P Munster, D Marchion, E Bicaku, M Lacevic, J Kim, B Centeno, A Daud, ...
Clinical cancer research 15 (7), 2488-2496, 2009
IgA transcytosis and antigen recognition govern ovarian cancer immunity
S Biswas, G Mandal, KK Payne, CM Anadon, CD Gatenbee, RA Chaurio, ...
Nature 591 (7850), 464-470, 2021
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
S Thomas, KT Thurn, E Biçaku, DC Marchion, PN Münster
Breast cancer research and treatment 130, 437-447, 2011
Selective inhibition of histone deacetylase 2 silences progesterone receptor–mediated signaling
E Biçaku, DC Marchion, ML Schmitt, PN Münster
Cancer research 68 (5), 1513-1519, 2008
Metabolic vulnerabilities in endometrial cancer
FL Byrne, IKH Poon, SC Modesitt, JL Tomsig, JDY Chow, ME Healy, ...
Cancer research 74 (20), 5832-5845, 2014
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival
DC Marchion, HM Cottrill, Y Xiong, N Chen, E Bicaku, WJ Fulp, N Bansal, ...
Clinical Cancer Research 17 (19), 6356-6366, 2011
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
AI Daud, J Dawson, RC DeConti, E Bicaku, D Marchion, S Bastien, ...
Clinical Cancer Research 15 (7), 2479-2487, 2009
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
DC Marchion, E Bicaku, AI Daud, DM Sullivan, PN Munster
Molecular cancer therapeutics 4 (12), 1993-2000, 2005
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
Y Cao, J Trillo-Tinoco, RA Sierra, C Anadon, W Dai, E Mohamed, L Cen, ...
Nature communications 10 (1), 1280, 2019
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells
KK Payne, JA Mine, S Biswas, RA Chaurio, A Perales-Puchalt, ...
Science 369 (6506), 942-949, 2020
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition
JG Turner, DC Marchion, JL Dawson, MF Emmons, LA Hazlehurst, ...
Cancer research 69 (17), 6899-6905, 2009
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ
DC Marchion, E Bicaku, JG Turner, AI Daud, DM Sullivan, PN Munster
Clinical cancer research 11 (23), 8467-8475, 2005
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
DC Marchion, E Bicaku, JG Turner, ML Schmitt, DR Morelli, PN Munster
Molecular cancer therapeutics 8 (4), 794-801, 2009
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20